Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Search
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Pride Month and our culture of respect
Watch our colleagues from the LGBTQIA+ community and allies share their views.
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Zoonotic diseases things you should know
Zoonotic diseases can be transmitted between animals and humans. They are more common than you may think – and they are on the rise. Find out how this affects you.
TCO patient podcasts
From clinical trials to living with cancer, hear patient perspectives on different cancer topics in this podcast series.
Artrial Fibrillation
Artrial Fibrillation
GPP
GPP
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
Horses
Horses
Lung Diseases
Lung Diseases
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Scouting for digital innovation
Get to know our digital scouts who look-out for emerging technologies and trends that could benefit our patients.
Patient Centricity
Patient Centricity
Our Responsibility
Human Health Our Responsibility
Veterinary Public Health
Veterinary Public Health
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
Future of Diabetes
This video highlights the evolution of type 2 diabetes management
Accessibility Statement
Accessability Statement
Heart Diseases
Heart Diseases
Full data chronic kidney disease trial efficacy
Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
Breakthrough introduction innovation pet parasiticides
In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
Ivan Blanarik Therapeutic Area Head Respiratory
Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
Our mission in cardiovascular, renal, and metabolic care
Interconnected cardiovascular, renal, and metabolic diseases affect over 1 billion lives globally
Global Careers Page
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.